Tag: MK 0893

Abstract The vision of the future health care should MK 0893 be a method in which patient care is consistently improved through the use of info on the individual patient’s genomes and their downstream products. trans-disciplinary scientists INSR on a pan-European level through programs such as the Assistance in Technology and Technology (COST) can support capacity building and increase the effect of personalized medicine study on regulatory body decision makers pharmaceutical and insurance companies and the spending general public. Such group effort could enable breakthrough scientific developments leading to new ideas and products and thereby contributing to the conditioning of Europe’s study and innovation capacity while reforming the health care system. Fundamental technology within the genetic background of individual receptiveness toward medicines offers progressed over the years. Variations in metabolic capacity have been for example in the focus of the 1st the Assistance in Technology and Technology action in biomedicine (COST B1 1986 Since then progress has been made in the research within the pharmacodynamic element to clarify individual vulnerability. Lately additional progress has been made owing to innovative tools for diagnosis in the molecular level leading continuously into a transformation of the health care system; a transformation fueled by the adoption and the rapid developments of information and communication technology (ICT) genomics and related disciplines as well as the cultural drivers of personalized medicine (1). The virtual patient model enabled by personalized ICT services and providing genetic and genomic information of every individual based on a laboratory-on-chip technology and bio-nanotechnology promises personalized medication and genome profiles and other “-omics” of individuals (2). Personalized medical care is designed to get the individual patient a drug that will be therapeutically active while minimizing the adverse effects. Personalized medicine encompasses not only tailor-made drugs at the correct dose for the right patient but also incorporates management of our personal data and clinical information (3). Realizing the potential of personalized medicine requires new methods for processing of the deluge of genomic data and translation of the findings into medical practice (2). Biology is being captured in software and hardware through the modeling of genes proteins cells and human organs. This theoretical abstraction of biology into accurate models involves the disciplines of mathematics physics and chemistry while data gathering simulation and visualization MK 0893 MK 0893 are involving all aspects of ICT. The upheaval in MK 0893 the life sciences enabled by ICT requires new computing capabilities sophisticated MK 0893 algorithms a vast range of software products internet technologies as well as advanced data management capabilities for the large torrent of data. The creation of the virtual patient model a personal simulation of the human body becomes mandatory for a faster reliable and successful health care system. The development of affordable next-generation high-throughput technologies allows generation of data from the entire genome transcriptome epigenome etc from a single (routine) clinical specimen (4 5 These technologies are expected to influence the fundamentals of the current practice of “reactive” medicine to a more systemic structured and evidence-based approach to change the current classification/definition of disease entities and to influence to a great extent the therapeutic protocols. As a consequence ICT is a fundamental part of the process of understanding the human body and life in itself as a complex biological system speeding-up the whole drug discovery/development process providing new targets for selective inhibitors and reducing costs. The appropriate use of ICTs is probably the most important strategy to translate information from MK 0893 “-omics” research into clinically relevant products and technologies and revolutionize life sciences. Challenges and opportunities The numerous challenges faced by scientists slow the progress in personalized medicine subsequently delaying the advantages and the opportunities for the patients. Identifying each individual’s reaction for absolute personalized medicine is usually neither easy and straightforward from a research perspective nor practical from a pharmaceutical diagnostic or prognostic perspective. Stratification of the.